Shopping Cart
- Remove All
- Your shopping cart is currently empty
S21-1011 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 0.059 μM for eqBChE and 0.162 μM for hBChE. This compound displays favorable pharmacokinetic properties, including effective blood-brain barrier (BBB) permeability. Furthermore, S21-1011 activates the keap1-Nrf2-ARE pathway, with an EC50 of 23.48 μM for activating the antioxidant element ARE, and has been shown to improve cognitive function in a murine model of Alzheimer’s disease.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | S21-1011 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 0.059 μM for eqBChE and 0.162 μM for hBChE. This compound displays favorable pharmacokinetic properties, including effective blood-brain barrier (BBB) permeability. Furthermore, S21-1011 activates the keap1-Nrf2-ARE pathway, with an EC50 of 23.48 μM for activating the antioxidant element ARE, and has been shown to improve cognitive function in a murine model of Alzheimer’s disease. |
Targets&IC50 | eqBCHE:0.059 μM, hBCHE:0.162 μM |
Molecular Weight | 464.60 |
Formula | C30H32N4O |
Cas No. | 2671859-87-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.